Drugs / MG7-CART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02862704 | Jun 2016 → May 2017 | — | Xijing Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MG7-CART | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02862704 ↗ |
| Modality | Cell therapy | “Designer T cells are prepared by PBMC which from patients by leukapheresis, and then activated and re-engineered to express chimeric antigen receptors (CARs) specific for MG7,...” NCT02862704 ↗ |
| Route | Other | “intra-tumor injection” NCT02862704 ↗ |